sb-223412 and Urinary-Incontinence

sb-223412 has been researched along with Urinary-Incontinence* in 1 studies

Reviews

1 review(s) available for sb-223412 and Urinary-Incontinence

Article	Year
Talnetant GlaxoSmithKline. Current opinion in investigational drugs (London, England : 2000), 2005, Volume: 6, Issue:7 Talnetant (SB-223412) is a selective, orally active NK3 antagonist based on 4-quinolinecarboxamide, and is under development by GlaxoSmithKline (formerly SmithKline Beecham) for the potential treatment of several disorders, including urinary incontinence, irritable bowel syndrome and schizophrenia. By November 2004, the compound had completed phase II trials. Topics: Animals; Clinical Trials, Phase II as Topic; Humans; Irritable Bowel Syndrome; Molecular Structure; Quinolines; Receptors, Tachykinin; Schizophrenia; Treatment Outcome; Urinary Incontinence	2005

Article

Year

Current opinion in investigational drugs (London, England : 2000), 2005, Volume: 6, Issue:7

Talnetant (SB-223412) is a selective, orally active NK3 antagonist based on 4-quinolinecarboxamide, and is under development by GlaxoSmithKline (formerly SmithKline Beecham) for the potential treatment of several disorders, including urinary incontinence, irritable bowel syndrome and schizophrenia. By November 2004, the compound had completed phase II trials.

Topics: Animals; Clinical Trials, Phase II as Topic; Humans; Irritable Bowel Syndrome; Molecular Structure; Quinolines; Receptors, Tachykinin; Schizophrenia; Treatment Outcome; Urinary Incontinence

2005